Galapagos NV (BVMF:G1LP34)

Market Cap	11.45B
Revenue (ttm)	1.79B
Net Income (ttm)	-2.73B
Shares Out	n/a
EPS (ttm)	-41.38
PE Ratio	n/a
Forward PE	13.06
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5
Average Volume	38
Open	8.57
Previous Close	8.55
Day's Range	8.57 - 8.60
52-Week Range	6.48 - 10.00
Beta	-0.05
RSI	48.08
Earnings Date	Nov 5, 2025

About Galapagos NV

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 704
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: G1LP34

Financial Performance

In 2024, Galapagos NV's revenue was 275.65 million, an increase of 14.99% compared to the previous year's 239.72 million. Earnings were 74.08 million, a decrease of -65.01%.

Financial numbers in EUR